MacroGenics Q3 net loss narrows to $24.8M; receives $60M Gilead upfront; cash runway into mid-2024

MACROGENICS INC

2022-Q3 EPS reported -$2.16 revenue$78,842,000

Q3 total revenue $41.7M (up from $15.7M YoY) including $30M Incyte milestone and $4.4M MARGENZA sales.
Net loss $24.8M ($0.40/share) vs $52.9M ($0.86/share) in Q3 2021; R&D spend $48.2M.
Cash $123.6M at Sep 30, plus $60M from Gilead in Oct; cash runway extended into mid-2024.
Gilead collaboration for MGD024 and up to two bispecific programs; potential $1.7B in milestones plus tiered royalties.
Teplizumab PDUFA date Nov 17, 2022; if approved, MacroGenics eligible for $60M milestone from Provention Bio.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MACROGENICS INC reported the quarter ended September 30, 2022 results: revenue $41.7 million.

Period: the quarter ended September 30, 2022
Revenue: $41.7 million
Result: reported results

Exact text from the filing

Total revenue, consisting primarily of revenue from collaborative agreements, was $41.7 million for the quarter ended September 30, 2022, compared to total revenue of $15.7 million for the quarter ended September 30, 2021.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

MACROGENICS INC filing history →

Source: SEC EDGAR

accession 0001125345-22-000103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.